A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly

Beatriz Gras-Miralles,1 Filippo Cremonini1,21Gastroenterology Department, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 2Southern Nevada VA Healthcare System, Las Vegas, NV, USAAbstract: Chronic constipation is a common disorder in the general population, with higher...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gras-Miralles B, Cremonini F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Lubiprostone chronic constipation irritable bowel syndrome Parkinson's disease opioids elderly. Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/106a653b0fde471198202aa486bfe912
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:106a653b0fde471198202aa486bfe912
record_format	dspace
spelling	oai:doaj.org-article:106a653b0fde471198202aa486bfe9122021-12-02T07:59:07ZA critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly1178-1998https://doaj.org/article/106a653b0fde471198202aa486bfe9122013-02-01T00:00:00Zhttps://www.dovepress.com/a-critical-appraisal-of-lubiprostone-in-the-treatment-of-chronic-const-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Beatriz Gras-Miralles,1 Filippo Cremonini1,21Gastroenterology Department, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 2Southern Nevada VA Healthcare System, Las Vegas, NV, USAAbstract: Chronic constipation is a common disorder in the general population, with higher prevalence in the elderly, and is associated with worse quality of life and with greater health care utilization. Lubiprostone is an intestinal type-2 chloride channel activator that increases intestinal fluid secretion, small intestinal transit, and stool passage. Lubiprostone is currently approved by the US Food and Drug Administration for the treatment of chronic idiopathic constipation and of irritable bowel syndrome with predominant constipation. This review outlines current approaches and limitations in the treatment of chronic constipation in the elderly and discusses the results, limitations, and applicability of randomized, controlled trials of lubiprostone that have been conducted in the general and elderly population, with additional focus on the use of lubiprostone in constipation in Parkinson's disease and in opioid-induced constipation, two clinical entities that can be comorbid in elderly patients.Keywords: irritable bowel syndrome, Parkinson's disease, opioid-induced constipation, chronic constipationGras-Miralles BCremonini FDove Medical PressarticleLubiprostonechronic constipationirritable bowel syndromeParkinson's diseaseopioidselderly.GeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 191-200 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Lubiprostone chronic constipation irritable bowel syndrome Parkinson's disease opioids elderly. Geriatrics RC952-954.6
spellingShingle	Lubiprostone chronic constipation irritable bowel syndrome Parkinson's disease opioids elderly. Geriatrics RC952-954.6 Gras-Miralles B Cremonini F A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly
description	Beatriz Gras-Miralles,1 Filippo Cremonini1,21Gastroenterology Department, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 2Southern Nevada VA Healthcare System, Las Vegas, NV, USAAbstract: Chronic constipation is a common disorder in the general population, with higher prevalence in the elderly, and is associated with worse quality of life and with greater health care utilization. Lubiprostone is an intestinal type-2 chloride channel activator that increases intestinal fluid secretion, small intestinal transit, and stool passage. Lubiprostone is currently approved by the US Food and Drug Administration for the treatment of chronic idiopathic constipation and of irritable bowel syndrome with predominant constipation. This review outlines current approaches and limitations in the treatment of chronic constipation in the elderly and discusses the results, limitations, and applicability of randomized, controlled trials of lubiprostone that have been conducted in the general and elderly population, with additional focus on the use of lubiprostone in constipation in Parkinson's disease and in opioid-induced constipation, two clinical entities that can be comorbid in elderly patients.Keywords: irritable bowel syndrome, Parkinson's disease, opioid-induced constipation, chronic constipation
format	article
author	Gras-Miralles B Cremonini F
author_facet	Gras-Miralles B Cremonini F
author_sort	Gras-Miralles B
title	A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly
title_short	A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly
title_full	A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly
title_fullStr	A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly
title_full_unstemmed	A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly
title_sort	critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/106a653b0fde471198202aa486bfe912
work_keys_str_mv	AT grasmirallesb acriticalappraisaloflubiprostoneinthetreatmentofchronicconstipationintheelderly AT cremoninif acriticalappraisaloflubiprostoneinthetreatmentofchronicconstipationintheelderly AT grasmirallesb criticalappraisaloflubiprostoneinthetreatmentofchronicconstipationintheelderly AT cremoninif criticalappraisaloflubiprostoneinthetreatmentofchronicconstipationintheelderly
_version_	1718398706804326400

A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly

Ejemplares similares